JAY CROSS
Corporate Board Profile
Tech Score:
0
/100
← Back to All Directors
Sonnet BioTherapeutics Holdings, Inc.
Filing Date
Source Excerpt
2022-08-25
Jay Cross 78,214 shares (7) **
Data sourced from SEC filings. Last updated: 2026-02-03